OTLK
Outlook Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Price History
Fundamentals
| Market Cap | $218.42M |
| P/E Ratio (TTM) | - |
| Forward P/E | -6.68 |
| EPS (TTM) | $-1.13 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | - |
| Recommendation | Buy 2.0 |
| Analyst Target | $5.50 |
| Analysts | 3 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 66.5 |
| Beta | 0.98 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.39 |
| 52-Week Low | $0.16 |
| 50-Day Avg | $0.73 |
| 200-Day Avg | $0.90 |
| Avg Volume | $19.21M |
| Volume | $8.77M |
Performance Analysis
BULLISHOTLK shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:25 UTC
Back to Screener Export Report